CF PharmTech, Inc. 2025 Annual Report: Key Highlights and Investor Analysis

Executive Summary

CF PharmTech, Inc. (Stock Code: 2652), a leading player in inhalation drug delivery and respiratory therapies in China, released its 2025 annual report. The company completed its IPO on the Hong Kong Stock Exchange on October 8, 2025, raising significant capital to support its ambitious pipeline and growth strategies. The year was marked by both operational challenges and strategic progress, with several details that are highly relevant for current and prospective shareholders.

Financial Performance

• Revenue Decline: The company reported revenue of RMB432.5 million in 2025, a significant decrease from RMB607.8 million in 2024. This decline was primarily attributed to the centralized volume-based procurement (VBP) renewal affecting its main product, CF017.
• Profitability Impacted: Net profit dropped sharply to RMB2.5 million in 2025, down from RMB21.1 million in 2024. The decline is linked to lower sales and compressed margins due to VBP inclusion.
• Adjusted Profit (Non-IFRS): After adding back share-based payment expenses and listing expenses, adjusted profit (non-IFRS) stood at RMB31.8 million in 2025, compared to RMB51.9 million in 2024.
• No Dividend: The Board did not recommend any dividend for 2025, citing the need to preserve cash for operations and R&D investments.
• Strong Liquidity and Cash Position: As of December 31, 2025, the company held substantial cash resources, including RMB325.4 million in USD (mainly from IPO proceeds), and RMB238.3 million in redeemable low-risk structured deposits.

IPO and Use of Proceeds

• Successful Hong Kong Listing: The company’s IPO raised net proceeds of approximately HK\$525.4 million, with a net price per H share of HK\$12.75 (the listing price was HK\$14.75; closing price on debut was HK\$38.5).
• Proceeds Allocation: The funds are earmarked for R&D, clinical development, commercialization of inhalation products, pipeline investment, and manufacturing upgrades, with most proceeds expected to be utilized by December 31, 2027.

Strategic and Operational Developments

• Product Concentration Risk: The company remains heavily reliant on CF017, which faces pressure from centralized procurement. The VBP cycle for CF017 extends through 2028, but further price cuts or removal from the VBP catalogue would materially impact revenue and profits.
• Pipeline Progress: The company achieved or surpassed key R&D milestones, including IND filings for ICF001 and ICF004, NDA filings for nasal spray products, and advancements in its inhaled siRNA platform.
• R&D and Staff Investment: R&D expenses remained high at RMB124.5 million, and the company maintained a workforce of 540 employees. Total remuneration for 2025 was RMB132.4 million.
• No Major Acquisitions/Disposals: There were no material acquisitions, disposals, or new commitments for capital assets during the reporting period.

Share Repurchase Program

• Active Share Buyback: In December 2025, shareholders approved a share repurchase mandate. By the end of February 2026, the company had repurchased a total of 496,500 H shares at an aggregate consideration of HK\$17.7 million. These shares are held as treasury shares, to be used for incentive schemes or resale, potentially supporting future share price.

Balance Sheet and Capital Structure

• Gearing Ratio: The company’s gearing ratio (total liabilities/total assets) improved to 17.34% (from 25.4% in 2024), reflecting strengthened capital following the IPO.
• No Defaults: The company did not breach any loan covenants and reported no defaults in 2025.
• No Convertible Securities or Warrants: No new convertible securities, options, or equity-linked instruments were issued.

Risk Factors and Outlook

• VBP Exposure: CF017’s inclusion in VBP has increased hospital coverage but compressed prices and gross margins. Future VBP negotiations or loss of procurement status are key risks.
• Pipeline Execution: Timely execution of R&D programs and successful commercialization of new products will be crucial for medium-term recovery and growth.
• FX Exposure: The company has increased USD holdings post-IPO. While there is currently no hedging policy, management may consider FX hedging if exposure remains high.
• Dividend Policy: No formal dividend policy is in place. Management will review the possibility as profitability and cash flows stabilize.
• Strategic Flexibility: Management expects to fund operations and capital needs from internal resources, bank borrowings, and remaining IPO proceeds. Opportunistic financing may be considered for value-accretive initiatives.

Corporate Governance and Compliance

• Governance Practices: The company is in compliance with the Hong Kong Corporate Governance Code since the Listing Date. There were no connected transactions or material litigation during the reporting period.
• Shareholder Rights: Public float is healthy at 56.1%. Shareholders have the right to convene meetings and put forward proposals.
• ESG Focus: The company maintains a strong commitment to ESG, with a separate ESG report to be published alongside the annual report.

Potential Price-Sensitive Information for Investors

• Significant Revenue and Profit Drop: The sharp decrease in revenue and profitability, mainly due to VBP effects on CF017, could weigh on the share price if not offset by pipeline progress or new growth drivers.
• Share Repurchase: The ongoing buyback may provide short-term support to the share price and signals management’s confidence in undervaluation or future prospects.
• IPO Proceeds and Cash Position: The substantial cash buffer and prudent capital management reduce financial risk, supporting strategic investments and resilience.
• No Dividend: The continued suspension of dividends may disappoint some income-focused investors but supports reinvestment in growth.
• Pipeline Achievements: On-track or ahead-of-schedule pipeline milestones could provide medium-term catalysts if commercialized successfully.

Outlook for 2026 and Beyond

Management expects 2026 to be a pivotal year for recovery and structural upgrading, with improved visibility for CF017, expanded hospital coverage, and further progress in R&D. The company is included in the Hang Seng Composite Index and eligible for Stock Connect, enhancing trading liquidity and market recognition.

Disclaimer

This article is a summary and analysis of CF PharmTech, Inc.’s 2025 Annual Report, intended for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. Market conditions and company fundamentals may change, and past performance is not indicative of future results.

View CF PHARMTECH Historical chart here